Polyketide synthases (PKSs) manufacture truly remarkable natural products. Polyketides are structurally diverse and possess important medicinal and agricultural capabilities that include but are not limited to: antibacterial, anticancer, antiparasitic, immunosuppressant, herbicidal, insecticidal and fungicidal activities. Assembly-line PKSs are a subset of type I PKSs and are exceptionally complex molecular machines. For example, the extensively studied 6-deoxyerythronolide B synthase (DEBS) is a colossal homodimer (its molecular weight exceeds 2 MDa) that elaborately channels reactive intermediates through 22 distinct enzymatic domains to build 6-deoxyerythronolide B (6-dEB), a precursor of the antibiotic erythromycin A ([@bib23]; [@bib10]; [@bib3]; [@bib4]) ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1The 6-Deoxyerythronolide B Synthase (DEBS). Enzymatic domains: KS, ketosynthase; AT, acyltransferase; DH, dehydratase; KR, ketoreductase; ER, enoylreductase; ACP, acyl carrier protein; and TE, thioesterase.Fig. 1

Unfortunately, assembly-line PKSs often are housed in poorly characterized and/or difficult to culture microbes. Further, many of the biosynthetic gene clusters (BGCs) involve with these PKSs are not expressed in laboratory conditions ([@bib20]). Although game-changing tools such as the CRISPR/Cas system are being repurposed for *Streptomyces* -- a treasure trove for assembly-line PKSs -- ([@bib2]), bacteria like *Streptomyces* have slow growth rates, are labor- and time-intensive to genetically manipulate and have cluttered metabolic backgrounds. On the other hand, model strains of *Escherichia coli* are obvious "user-friendly" workhorses. They are easy to culture, grow fast and have a wealth of genetic tools. Importantly, their metabolic backgrounds are free from native complex natural product biosynthetic pathways, which lowers the potential for metabolic 'cross-talk' with heterologously introduced systems. Despite *E. coli*'s advantages, only a handful of assembly-line PKSs have been either fully or largely reconstituted in *E. coli*. Here in this brief perspective, we summarize the most successful case -- DEBS -- of using *E. coli* as a heterologous host for assembly-line polyketide biosynthesis. Finally, we propose examples of future challenges and opportunities that researchers exploiting *E. coli* as a tool may consider as avenues to further our understanding of these breathtaking enzymes.

Following the accomplishments of manipulating DEBS in both its native producer host *Saccharopolyspora erythraea* ([@bib14]) as well as *Streptomyces* hosts ([@bib9]; [@bib25]), the stage was set for its reconstituted biosynthesis in *E. coli*. Pfeifer et al. expressed the three large DEBS polypeptides (their molecular weights each surpass 300 kDa, and their genes are each longer than 10 kb) in a highly engineered *E. coli* BL21(DE3) derivative named BAP1 ([@bib17]) and synthesized 6-dEB at titers of 20 mg/L in *E. coli*. BAP1 encodes *Bacillus subtilis* Sfp, a phosphopantetheinyl transferase that phosphopantetheinylates the seven acyl carrier protein domains in DEBS. To elevate intracellular concentrations of propionyl-CoA and methylmalonyl-CoA, Pfeifer et al. a) deleted the propionate catabolism genes prpRBCD, b) boosted expression of the propionyl-CoA synthetase PrpE and c) co-expressed Streptomyces coelicolor propionyl-CoA carboxylase, which generates methylmalonyl-CoA from propionyl-CoA. Lau et al. achieved titers that approached Streptomyces hosts (1.1 g/L) by optimizing the medium composition and fermentation conditions ([@bib12]). Installing DEBS in E. coli enabled the engineers to rationally modify specific parts of DEBS to fabricate novel natural polyketides in vivo, a long-standing goal in natural products research. To manufacture a benzoate-containing analog of 6-dEB, Pfeifer et al. replaced the loading module of DEBS with the loading module from the rifamycin polyketide synthase, which accepts a benzoate starter unit. To completely produce erythromycin A in E. coli, Zhang et al. impressively expressed 17 additional genes that are responsible for deoxysugar biosynthesis, macrolide tailoring, and resistance, which led to the biosynthesis of erythromycin A at titers of 0.6 mg/L ([@bib26]). P8/1-OG (an intermediate of rifamycin biosynthesis) ([@bib24]) and epothilone C and D ([@bib15]) are two other working examples of engineered assembly-line polyketide biosynthesis in E. coli. While these two studies did not reconstitute the entire assembly-line, they are notable for utilizing chaperones and protein dissection to enhance the expression of massive PKS polypeptides: the 530 kDa RifA and 765 kDa EpoD proteins were each split into two polypeptides. Even assembly-line systems that are predominantly composed of non-ribosomal peptide synthetase (NRPS) domains such as the yersiniabactin NRPS/PKS can be successfully expressed in E. coli ([@bib18]).

Engineering erythromycin A biosynthesis in *E. coli* represents a high-water mark for PKS research. However, one could argue that the small number of pathways targeted for engineered assembly-line polyketide biosynthesis in *E. coli* suggests that *E. coli* is a poor "universal host". Certainly, as seen in the previous examples, *E. coli* requires nontrivial engineering for the correct post-translational modifications of PKSs, sufficient precursor pools and efficient translation/folding of enormous polypeptides. Notwithstanding these difficulties, *E. coli* is poised to continue as a top heterologous host for assembly-line PKSs. Here are three -- while not exhaustive -- examples of challenges and opportunities in which *E. coli* should remain in the priority list for assembly-line PKS enzymologists.

First, *trans*-acyltransferase (*trans*-AT) assembly-line PKSs represent almost 38% of all assembly line PKSs according to a recent survey ([@bib16]). Unlike *cis*-AT PKSs such as DEBS, *trans*-AT PKSs need AT domains encoded outside of the core polyketide synthase genes that interact noncovalently with the megasynthase. However, the understanding of *trans*-AT PKSs has significantly lagged behind that of *cis*-AT PKSs ([@bib7]). *trans*-AT PKSs are particularly challenging to study because they frequently originate in poorly understood microbes as well as possess a wide array of unorthodox biosynthetic components. As of this writing, no *trans*-AT assembly-line PKS has been reconstituted in *E. coli*; therefore, the lessons learned from the first fruitful attempts will be invaluable to researchers that desire to tap into the advantages that *E. coli* holds as a heterologous host.

Second, genomic sequencing has revealed large numbers (far surpassing known assembly-line PKS BGCs) of cryptic or "orphan" assembly-line PKS BGCs associated with no known polyketide products ([@bib16]). This recent surge provides a vast resource for pharmaceutical and agrochemical natural products research. However, scientists must endeavor to decipher this embarrassment of riches in a timely fashion. Though platforms such as antiSMASH 4.0 ([@bib1]), PRISM 3 ([@bib21]) and TransATor ([@bib8]) offer useful polyketide structural predictions, there is no substitute for interrogating PKSs and their repertoire of products either *in vitro* or *in vivo*. For example, the NOCardiosis-Associated Polyketide (NOCAP) synthase, an orphan assembly-line PKS found in clinical strains of the actinomycete *Nocardia*, exhibits iterative activity in one of its modules, a behavior which cannot be presently predicted *in silico* ([@bib11]). *E. coli* provides a way to quickly move from assembly-line PKS genes to natural products. *E. coli*'s aforementioned sizeable genetic toolkit, fast growth rate and uncluttered metabolic background should enable rapid and straightforward cloning of these clusters, polyketide biosynthesis and metabolic profiling. As in the case with *trans*-AT assembly-line PKSs, no assembly-line PKS identified *in silico* has been immediately "de-orphanized" by reconstitution in *E. coli*; this achievement would represent a new method of natural products discovery.

Third, although there have been major advances in the structural analysis of individual PKS domains, multidomain fragments and even intact modules ([@bib19]; [@bib5]; [@bib6]; [@bib13]), we know little about how these multienzyme machines behave as a whole in a cell. Transmission electron microscopy of *B. subtilis* cells revealed that the bacillaene hybrid PKS/NRPS fascinatingly assembles into a single organelle-like membrane-associated complex with approximate mass of 10--100 MDa ([@bib22]). It would be most interesting to establish how many assembly-line PKSs organize into "megacomplexes". Can microscopists study PKS complex dynamics with live-cell imaging, as oppose to electron microscopy which is limited to fixed cells? Do PKSs retain the ability to assemble as a megacomplex in a heterologous host like *E. coli*? If so, then pathways previously engineered to operate in *E. coli* could be easily retrofitted with a variety of fluorescent proteins or tags; therefore, permitting the monitoring of these enzymes with live-cell imaging tools that require fluorophores such as fluorescence or super-resolution microscopy. Once tagged, these proteins can be interrogated "coarsely" in the context of megacomplexes or "finely" in the context of domain-domain interactions with techniques such as FRET (Fluorescence Resonance Energy Transfer).
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